The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Self-amplifying RNA (saRNA) Drugs Market Research Report 2025
Synopsis
saRNA is an RNA that shares many structural similarities with mRNA: it is a linear, single-stranded RNA molecule synthesized from a 5' cap, a 3' poly(A) tail, and 5' and 3' UTRs. The main difference is that saRNA is a larger molecule because it encodes four additional proteins in addition to the vaccine antigen or gene of interest. These four additional proteins are nonstructural proteins, usually derived from alphaviruses, encoding replicase enzymes. This replicase is able to amplify the original RNA strand upon delivery to cells, resulting in higher amounts of protein expression with minimal RNA dosage required.
The global Self-amplifying RNA (saRNA) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Self-amplifying RNA (saRNA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Self-amplifying RNA (saRNA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Self-amplifying RNA (saRNA) Drugs include Chimeron Bio, Ziphius Vaccines, Aldevron, VaxEquity, Precision Nanosystems, Replicate Bioscience, Elixirgen Therapeutics, Immorna and CSL, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Self-amplifying RNA (saRNA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Self-amplifying RNA (saRNA) Drugs.
Report Scope
The Self-amplifying RNA (saRNA) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Self-amplifying RNA (saRNA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Self-amplifying RNA (saRNA) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Chimeron Bio
Ziphius Vaccines
Aldevron
VaxEquity
Precision Nanosystems
Replicate Bioscience
Elixirgen Therapeutics
Immorna
CSL
Arcturus Therapeutics
Segment by Type
Preventive Medicine
Medicine
Segment by Application
Infectious Disease
Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Self-amplifying RNA (saRNA) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Self-amplifying RNA (saRNA) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
saRNA is an RNA that shares many structural similarities with mRNA: it is a linear, single-stranded RNA molecule synthesized from a 5' cap, a 3' poly(A) tail, and 5' and 3' UTRs. The main difference is that saRNA is a larger molecule because it encodes four additional proteins in addition to the vaccine antigen or gene of interest. These four additional proteins are nonstructural proteins, usually derived from alphaviruses, encoding replicase enzymes. This replicase is able to amplify the original RNA strand upon delivery to cells, resulting in higher amounts of protein expression with minimal RNA dosage required.
The global Self-amplifying RNA (saRNA) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Self-amplifying RNA (saRNA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Self-amplifying RNA (saRNA) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Self-amplifying RNA (saRNA) Drugs include Chimeron Bio, Ziphius Vaccines, Aldevron, VaxEquity, Precision Nanosystems, Replicate Bioscience, Elixirgen Therapeutics, Immorna and CSL, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Self-amplifying RNA (saRNA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Self-amplifying RNA (saRNA) Drugs.
Report Scope
The Self-amplifying RNA (saRNA) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Self-amplifying RNA (saRNA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Self-amplifying RNA (saRNA) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Chimeron Bio
Ziphius Vaccines
Aldevron
VaxEquity
Precision Nanosystems
Replicate Bioscience
Elixirgen Therapeutics
Immorna
CSL
Arcturus Therapeutics
Segment by Type
Preventive Medicine
Medicine
Segment by Application
Infectious Disease
Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Self-amplifying RNA (saRNA) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Self-amplifying RNA (saRNA) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Self-amplifying RNA (saRNA) Drugs Market Overview
1.1 Product Overview and Scope of Self-amplifying RNA (saRNA) Drugs
1.2 Self-amplifying RNA (saRNA) Drugs Segment by Type
1.2.1 Global Self-amplifying RNA (saRNA) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Preventive Medicine
1.2.3 Medicine
1.3 Self-amplifying RNA (saRNA) Drugs Segment by Application
1.3.1 Global Self-amplifying RNA (saRNA) Drugs Market Value by Application: (2024-2030)
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Others
1.4 Global Self-amplifying RNA (saRNA) Drugs Market Size Estimates and Forecasts
1.4.1 Global Self-amplifying RNA (saRNA) Drugs Revenue 2019-2030
1.4.2 Global Self-amplifying RNA (saRNA) Drugs Sales 2019-2030
1.4.3 Global Self-amplifying RNA (saRNA) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Self-amplifying RNA (saRNA) Drugs Market Competition by Manufacturers
2.1 Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Self-amplifying RNA (saRNA) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Self-amplifying RNA (saRNA) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Self-amplifying RNA (saRNA) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Self-amplifying RNA (saRNA) Drugs, Product Type & Application
2.7 Self-amplifying RNA (saRNA) Drugs Market Competitive Situation and Trends
2.7.1 Self-amplifying RNA (saRNA) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Self-amplifying RNA (saRNA) Drugs Players Market Share by Revenue
2.7.3 Global Self-amplifying RNA (saRNA) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Self-amplifying RNA (saRNA) Drugs Retrospective Market Scenario by Region
3.1 Global Self-amplifying RNA (saRNA) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Self-amplifying RNA (saRNA) Drugs Global Self-amplifying RNA (saRNA) Drugs Sales by Region: 2019-2030
3.2.1 Global Self-amplifying RNA (saRNA) Drugs Sales by Region: 2019-2024
3.2.2 Global Self-amplifying RNA (saRNA) Drugs Sales by Region: 2025-2030
3.3 Global Self-amplifying RNA (saRNA) Drugs Global Self-amplifying RNA (saRNA) Drugs Revenue by Region: 2019-2030
3.3.1 Global Self-amplifying RNA (saRNA) Drugs Revenue by Region: 2019-2024
3.3.2 Global Self-amplifying RNA (saRNA) Drugs Revenue by Region: 2025-2030
3.4 North America Self-amplifying RNA (saRNA) Drugs Market Facts & Figures by Country
3.4.1 North America Self-amplifying RNA (saRNA) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2030)
3.4.3 North America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Self-amplifying RNA (saRNA) Drugs Market Facts & Figures by Country
3.5.1 Europe Self-amplifying RNA (saRNA) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2030)
3.5.3 Europe Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Self-amplifying RNA (saRNA) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Self-amplifying RNA (saRNA) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Self-amplifying RNA (saRNA) Drugs Market Facts & Figures by Country
3.7.1 Latin America Self-amplifying RNA (saRNA) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Self-amplifying RNA (saRNA) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Self-amplifying RNA (saRNA) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Self-amplifying RNA (saRNA) Drugs Sales by Type (2019-2030)
4.1.1 Global Self-amplifying RNA (saRNA) Drugs Sales by Type (2019-2024)
4.1.2 Global Self-amplifying RNA (saRNA) Drugs Sales by Type (2025-2030)
4.1.3 Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Self-amplifying RNA (saRNA) Drugs Revenue by Type (2019-2030)
4.2.1 Global Self-amplifying RNA (saRNA) Drugs Revenue by Type (2019-2024)
4.2.2 Global Self-amplifying RNA (saRNA) Drugs Revenue by Type (2025-2030)
4.2.3 Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Self-amplifying RNA (saRNA) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Self-amplifying RNA (saRNA) Drugs Sales by Application (2019-2030)
5.1.1 Global Self-amplifying RNA (saRNA) Drugs Sales by Application (2019-2024)
5.1.2 Global Self-amplifying RNA (saRNA) Drugs Sales by Application (2025-2030)
5.1.3 Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Self-amplifying RNA (saRNA) Drugs Revenue by Application (2019-2030)
5.2.1 Global Self-amplifying RNA (saRNA) Drugs Revenue by Application (2019-2024)
5.2.2 Global Self-amplifying RNA (saRNA) Drugs Revenue by Application (2025-2030)
5.2.3 Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Self-amplifying RNA (saRNA) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Chimeron Bio
6.1.1 Chimeron Bio Corporation Information
6.1.2 Chimeron Bio Description and Business Overview
6.1.3 Chimeron Bio Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Chimeron Bio Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.1.5 Chimeron Bio Recent Developments/Updates
6.2 Ziphius Vaccines
6.2.1 Ziphius Vaccines Corporation Information
6.2.2 Ziphius Vaccines Description and Business Overview
6.2.3 Ziphius Vaccines Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ziphius Vaccines Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.2.5 Ziphius Vaccines Recent Developments/Updates
6.3 Aldevron
6.3.1 Aldevron Corporation Information
6.3.2 Aldevron Description and Business Overview
6.3.3 Aldevron Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Aldevron Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.3.5 Aldevron Recent Developments/Updates
6.4 VaxEquity
6.4.1 VaxEquity Corporation Information
6.4.2 VaxEquity Description and Business Overview
6.4.3 VaxEquity Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 VaxEquity Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.4.5 VaxEquity Recent Developments/Updates
6.5 Precision Nanosystems
6.5.1 Precision Nanosystems Corporation Information
6.5.2 Precision Nanosystems Description and Business Overview
6.5.3 Precision Nanosystems Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Precision Nanosystems Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.5.5 Precision Nanosystems Recent Developments/Updates
6.6 Replicate Bioscience
6.6.1 Replicate Bioscience Corporation Information
6.6.2 Replicate Bioscience Description and Business Overview
6.6.3 Replicate Bioscience Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Replicate Bioscience Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.6.5 Replicate Bioscience Recent Developments/Updates
6.7 Elixirgen Therapeutics
6.6.1 Elixirgen Therapeutics Corporation Information
6.6.2 Elixirgen Therapeutics Description and Business Overview
6.6.3 Elixirgen Therapeutics Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Elixirgen Therapeutics Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.7.5 Elixirgen Therapeutics Recent Developments/Updates
6.8 Immorna
6.8.1 Immorna Corporation Information
6.8.2 Immorna Description and Business Overview
6.8.3 Immorna Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Immorna Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.8.5 Immorna Recent Developments/Updates
6.9 CSL
6.9.1 CSL Corporation Information
6.9.2 CSL Description and Business Overview
6.9.3 CSL Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CSL Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.9.5 CSL Recent Developments/Updates
6.10 Arcturus Therapeutics
6.10.1 Arcturus Therapeutics Corporation Information
6.10.2 Arcturus Therapeutics Description and Business Overview
6.10.3 Arcturus Therapeutics Self-amplifying RNA (saRNA) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Arcturus Therapeutics Self-amplifying RNA (saRNA) Drugs Product Portfolio
6.10.5 Arcturus Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Self-amplifying RNA (saRNA) Drugs Industry Chain Analysis
7.2 Self-amplifying RNA (saRNA) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Self-amplifying RNA (saRNA) Drugs Production Mode & Process
7.4 Self-amplifying RNA (saRNA) Drugs Sales and Marketing
7.4.1 Self-amplifying RNA (saRNA) Drugs Sales Channels
7.4.2 Self-amplifying RNA (saRNA) Drugs Distributors
7.5 Self-amplifying RNA (saRNA) Drugs Customers
8 Self-amplifying RNA (saRNA) Drugs Market Dynamics
8.1 Self-amplifying RNA (saRNA) Drugs Industry Trends
8.2 Self-amplifying RNA (saRNA) Drugs Market Drivers
8.3 Self-amplifying RNA (saRNA) Drugs Market Challenges
8.4 Self-amplifying RNA (saRNA) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Self-amplifying RNA (saRNA) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Self-amplifying RNA (saRNA) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Self-amplifying RNA (saRNA) Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Self-amplifying RNA (saRNA) Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Self-amplifying RNA (saRNA) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Self-amplifying RNA (saRNA) Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Self-amplifying RNA (saRNA) Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Self-amplifying RNA (saRNA) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Self-amplifying RNA (saRNA) Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Self-amplifying RNA (saRNA) Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Self-amplifying RNA (saRNA) Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Self-amplifying RNA (saRNA) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Self-amplifying RNA (saRNA) Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Self-amplifying RNA (saRNA) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Self-amplifying RNA (saRNA) Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Self-amplifying RNA (saRNA) Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Self-amplifying RNA (saRNA) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Self-amplifying RNA (saRNA) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Self-amplifying RNA (saRNA) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Self-amplifying RNA (saRNA) Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Self-amplifying RNA (saRNA) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Self-amplifying RNA (saRNA) Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Self-amplifying RNA (saRNA) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Self-amplifying RNA (saRNA) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Self-amplifying RNA (saRNA) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Self-amplifying RNA (saRNA) Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Self-amplifying RNA (saRNA) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Self-amplifying RNA (saRNA) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Self-amplifying RNA (saRNA) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Self-amplifying RNA (saRNA) Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Self-amplifying RNA (saRNA) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Self-amplifying RNA (saRNA) Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Self-amplifying RNA (saRNA) Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Self-amplifying RNA (saRNA) Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Self-amplifying RNA (saRNA) Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Self-amplifying RNA (saRNA) Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Self-amplifying RNA (saRNA) Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Self-amplifying RNA (saRNA) Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Self-amplifying RNA (saRNA) Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Self-amplifying RNA (saRNA) Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Chimeron Bio Corporation Information
Table 71. Chimeron Bio Description and Business Overview
Table 72. Chimeron Bio Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Chimeron Bio Self-amplifying RNA (saRNA) Drugs Product
Table 74. Chimeron Bio Recent Developments/Updates
Table 75. Ziphius Vaccines Corporation Information
Table 76. Ziphius Vaccines Description and Business Overview
Table 77. Ziphius Vaccines Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Ziphius Vaccines Self-amplifying RNA (saRNA) Drugs Product
Table 79. Ziphius Vaccines Recent Developments/Updates
Table 80. Aldevron Corporation Information
Table 81. Aldevron Description and Business Overview
Table 82. Aldevron Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Aldevron Self-amplifying RNA (saRNA) Drugs Product
Table 84. Aldevron Recent Developments/Updates
Table 85. VaxEquity Corporation Information
Table 86. VaxEquity Description and Business Overview
Table 87. VaxEquity Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. VaxEquity Self-amplifying RNA (saRNA) Drugs Product
Table 89. VaxEquity Recent Developments/Updates
Table 90. Precision Nanosystems Corporation Information
Table 91. Precision Nanosystems Description and Business Overview
Table 92. Precision Nanosystems Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Precision Nanosystems Self-amplifying RNA (saRNA) Drugs Product
Table 94. Precision Nanosystems Recent Developments/Updates
Table 95. Replicate Bioscience Corporation Information
Table 96. Replicate Bioscience Description and Business Overview
Table 97. Replicate Bioscience Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Replicate Bioscience Self-amplifying RNA (saRNA) Drugs Product
Table 99. Replicate Bioscience Recent Developments/Updates
Table 100. Elixirgen Therapeutics Corporation Information
Table 101. Elixirgen Therapeutics Description and Business Overview
Table 102. Elixirgen Therapeutics Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Elixirgen Therapeutics Self-amplifying RNA (saRNA) Drugs Product
Table 104. Elixirgen Therapeutics Recent Developments/Updates
Table 105. Immorna Corporation Information
Table 106. Immorna Description and Business Overview
Table 107. Immorna Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Immorna Self-amplifying RNA (saRNA) Drugs Product
Table 109. Immorna Recent Developments/Updates
Table 110. CSL Corporation Information
Table 111. CSL Description and Business Overview
Table 112. CSL Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. CSL Self-amplifying RNA (saRNA) Drugs Product
Table 114. CSL Recent Developments/Updates
Table 115. Arcturus Therapeutics Corporation Information
Table 116. Arcturus Therapeutics Description and Business Overview
Table 117. Arcturus Therapeutics Self-amplifying RNA (saRNA) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Arcturus Therapeutics Self-amplifying RNA (saRNA) Drugs Product
Table 119. Arcturus Therapeutics Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Self-amplifying RNA (saRNA) Drugs Distributors List
Table 123. Self-amplifying RNA (saRNA) Drugs Customers List
Table 124. Self-amplifying RNA (saRNA) Drugs Market Trends
Table 125. Self-amplifying RNA (saRNA) Drugs Market Drivers
Table 126. Self-amplifying RNA (saRNA) Drugs Market Challenges
Table 127. Self-amplifying RNA (saRNA) Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Self-amplifying RNA (saRNA) Drugs
Figure 2. Global Self-amplifying RNA (saRNA) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Self-amplifying RNA (saRNA) Drugs Market Share by Type in 2023 & 2030
Figure 4. Preventive Medicine Product Picture
Figure 5. Medicine Product Picture
Figure 6. Global Self-amplifying RNA (saRNA) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Self-amplifying RNA (saRNA) Drugs Market Share by Application in 2023 & 2030
Figure 8. Infectious Disease
Figure 9. Cancer
Figure 10. Others
Figure 11. Global Self-amplifying RNA (saRNA) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Self-amplifying RNA (saRNA) Drugs Market Size (2019-2030) & (US$ Million)
Figure 13. Global Self-amplifying RNA (saRNA) Drugs Sales (2019-2030) & (K Units)
Figure 14. Global Self-amplifying RNA (saRNA) Drugs Average Price (US$/Unit) & (2019-2030)
Figure 15. Self-amplifying RNA (saRNA) Drugs Report Years Considered
Figure 16. Self-amplifying RNA (saRNA) Drugs Sales Share by Manufacturers in 2023
Figure 17. Global Self-amplifying RNA (saRNA) Drugs Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Self-amplifying RNA (saRNA) Drugs Players: Market Share by Revenue in 2023
Figure 19. Self-amplifying RNA (saRNA) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Self-amplifying RNA (saRNA) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Self-amplifying RNA (saRNA) Drugs Sales Market Share by Country (2019-2030)
Figure 22. North America Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Country (2019-2030)
Figure 23. United States Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Self-amplifying RNA (saRNA) Drugs Sales Market Share by Country (2019-2030)
Figure 26. Europe Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Country (2019-2030)
Figure 27. Germany Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Netherlands Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Self-amplifying RNA (saRNA) Drugs Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Region (2019-2030)
Figure 34. China Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Self-amplifying RNA (saRNA) Drugs Sales Market Share by Country (2019-2030)
Figure 42. Latin America Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Country (2019-2030)
Figure 43. Mexico Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Brazil Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Argentina Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Colombia Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Self-amplifying RNA (saRNA) Drugs Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Self-amplifying RNA (saRNA) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Self-amplifying RNA (saRNA) Drugs by Type (2019-2030)
Figure 53. Global Revenue Market Share of Self-amplifying RNA (saRNA) Drugs by Type (2019-2030)
Figure 54. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Self-amplifying RNA (saRNA) Drugs by Application (2019-2030)
Figure 56. Global Revenue Market Share of Self-amplifying RNA (saRNA) Drugs by Application (2019-2030)
Figure 57. Global Self-amplifying RNA (saRNA) Drugs Price (US$/Unit) by Application (2019-2030)
Figure 58. Self-amplifying RNA (saRNA) Drugs Value Chain
Figure 59. Self-amplifying RNA (saRNA) Drugs Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
